In vitro drug responses in primary and metastatic colorectal cancers

References

• Steele GD Jr. The national cancer data base report on colorectal cancer. Cancer 1994;74:1979–89.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481–8.
   PubMed Web of Science ®Google Scholar
• Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4811–14.
   PubMedGoogle Scholar
• Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001;13:275–86.
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, Liedo G, Flesh M, Mery-Mignard D, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450–6.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Hein W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Fign A, Wons R, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–19.
   PubMed Web of Science ®Google Scholar
• Alberts D, Salmon SE, Chen GH-S, Moon TE, Young L, Surwit EA. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chem Pharmacol 1981;6:253–64.
   PubMed Web of Science ®Google Scholar
• Tanigawa N, Morimoto H, Dohmae N, Shimomatsuya T, Takahashi K, Muraoka R. In vitro growth ability and chemosensitivity of gastric and colorectal cancer cells assessed with the human tumour clonogenic assay and the thymidine incorporation assay. Eur J Cancer 1992;28:31–4.
   PubMedGoogle Scholar
• Kern DM, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;82:582–8.
   PubMed Web of Science ®Google Scholar
• Fruehauf JP, Bosanquet AG. In vitro determination of drug response: a discussion of clinical applications. Princ Pract Oncol Updat 1993;7:1–17.
   Google Scholar
• Mehta R, Bornstein R, Yu I-R, Parker RJ, McLaren CE, Nguyen KP, Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 2001;66:225–37.
   PubMedGoogle Scholar
• Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002;87:8–16.
   PubMed Web of Science ®Google Scholar
• Haroun RI, Clatterbuck RE, Gibbons C, Burger PC, Parker RJ, Fruehof JP, Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol 2002;58:115–23.
   PubMedGoogle Scholar
• Liozzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003;189:1301–7.
   PubMedGoogle Scholar
• Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. A prospective study of the predictive value of extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 2004;66:365–75.
   PubMed Web of Science ®Google Scholar
• Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Levels of multidrug resistance (MDR1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998;4:389–98.
   PubMed Web of Science ®Google Scholar
• d'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalence of in vitro extreme chemotherapy resistance in resected non-small-cell lung cancer. Ann Thorac Surg 2006;81:440–7.
   PubMedGoogle Scholar
• d'Amato TA, Pettiford BL, Schubert MJ, Parker R, Ricketts WA, Luktich JD, Survival among patients with platinum resistance, locally advanced non-small cell cancer treated with platinum-based systemic therapy. Ann Surg Oncol 2009;16:2848–55.
   PubMedGoogle Scholar
• Verleye L, Coens C, Amant F, Extreme drug resistance for carboplatin predicts resistance to first-line therapy in advanced-stage ovarian cancer: results from the EORTC-GCG/NCIC-CTG neoadjuvant trial. Communication at the 12th Biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, 25–28 October 2008. Abstr 1422.
   Google Scholar
• Dept Health Human Services, Health Insurance Portability and Accountability Act of 1996 (HIPAA), 45 CFR Part 160.103: In General administrative requirements, Subpart A; and 45 CFR Parts 164.512 and 164.514: In Security and privacy, Subpart E, Prepared: 20 February 2003. Available online at: (www.wedi.org/snip/public/articles/45CFR160&164.pdf).
   Google Scholar
• Köhne C-H, Bruce C, Folprecht G, Audisio R. Role of new agents in the treatment of colorectal cancer. Surg Oncol 2004;13:75–81.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homeren M, Hrnissi A, Cassidy J, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Douillard J-V, Pirotta N, Alaki M, Gruia G, Awad L, Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6:81–91.
   PubMed Web of Science ®Google Scholar
• Goldberg R. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005;10:40–8.
   PubMed Web of Science ®Google Scholar
• Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131–8.
   PubMedGoogle Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Bevicizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperation Ocology Group Study E3200. J Clin Oncol 2007;25:1539–44.
   PubMed Web of Science ®Google Scholar
• Jaffer A, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal cancer. Invest New Drugs 1998;16:175–7.
   PubMedGoogle Scholar